Inspire Medical Systems, Inc. ( INSP ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Timothy Herbert - Founder, Chairman, CEO & President Ezgi Yagci - Vice President of Investor Relations Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good morning, everyone.
Inspire Medical tops third-quarter 2025 estimates as revenue climbs and gross margin improves, with full-year EPS guidance raised.
Baron Discovery Fund ended the quarter up 2.85% but underperformed its benchmark, the Russell 2000 Growth Index. Leading defense technology provider Kratos Defense & Security Solutions contributed to performance following a strong earnings report and continued momentum across its business segments. PAR Technology's shares fell during the quarter after the company lowered its full-year growth outlook to 15% from 20%.
Inspire Medical Systems, Inc. ( INSP ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Ezgi Yagci - Vice President of Investor Relations Timothy Herbert - Founder, Chairman, CEO & President Richard Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Adam Maeder - Piper Sandler & Co., Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Danielle Antalffy - UBS Investment Bank, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Michael Sarcone - Jefferies LLC, Research Division Christopher Pasquale - Nephron Research LLC Richard Newitter - Truist Securities, Inc., Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Michael Polark - Wolfe Research, LLC Michael Kratky - Leerink Partners LLC, Research Division Presentation Operator Good afternoon.
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $0.6 per share a year ago.
Inspire Medical's Inspire V system shows strong safety, faster surgeries, and higher patient adherence in new trials.
Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
Inspire Medical Systems faced a major setback after delays in the Inspire V launch, leading to slashed guidance and a sharp share price drop. Despite near-term volatility and margin pressure, the company's valuation now appears attractive at less than 3x sales, supported by a strong balance sheet. Management expects revenue growth to reaccelerate in 2026, offering comfort to long-term investors despite current uncertainty around margins.
Investors need to pay close attention to INSP stock based on the movements in the options market lately.
Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure.
Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Richard J. Buchholz - Chief Financial Officer Timothy P.
The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.